Eupraxia Pharmaceuticals Gross Profit

Eupraxia Pharmaceuticals (EPRX) currently reports a gross profit of $-320K as of June 2026. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $65B. Use the charts on this page to explore Eupraxia Pharmaceuticals's gross profit history and peer comparisons.

Eupraxia Pharmaceuticals's gross profit changed from $0 to $-320K (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eupraxia Pharmaceuticals's gross profit of $-320K is lower than the Healthcare sector average of $65B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Eupraxia Pharmaceuticals reported $-320K in gross profit as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-320K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $65B. From there, open related valuation or income-statement pages for Eupraxia Pharmaceuticals, and consider following EPRX for alerts when major investors trade the stock.